Does Medicaid Cover Mounjaro for Weight Loss in 2026? State-by-State Reality

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most state Medicaid programs do NOT cover Mounjaro for weight loss as of April 2026, only for type 2 diabetes management with prior authorization
• Only 7 states (California, New York, Massachusetts, Vermont, Rhode Island, Connecticut, Minnesota) provide any Medicaid coverage pathway for GLP-1 medications prescribed specifically for obesity
• Even in coverage states, prior authorization denial rates for weight-loss indications run 60-80% on first submission (Kaiser Family Foundation, 2025)
• The federal Anti-Kickback Statute prohibits manufacturer copay cards for Medicaid patients, eliminating the $25/month savings card option available to commercial insurance holders

Direct answer (40-60 words)

Medicaid does not cover Mounjaro for weight loss in 43 states as of April 2026. Seven states offer limited coverage for obesity treatment with strict BMI and comorbidity requirements. All states cover Mounjaro for type 2 diabetes with prior authorization. Federal law prohibits Medicaid patients from using manufacturer savings cards, leaving compounded tirzepatide as the primary affordable alternative.

Table of contents

1. The coverage gap: why Medicaid treats weight loss differently
2. State-by-state Medicaid coverage map (2026)
3. The seven states with obesity coverage pathways
4. How Medicaid covers Mounjaro for diabetes (not weight loss)
5. Prior authorization requirements and denial patterns
6. What most articles get wrong about Medicaid formularies
7. The federal prohibition on manufacturer assistance for Medicaid patients
8. Real patient cost scenarios across three states
9. When your provider codes the diagnosis: the off-label gray zone
10. The compounded tirzepatide alternative for Medicaid patients
11. How to verify your state's specific coverage in 10 minutes
12. FAQ

The coverage gap: why Medicaid treats weight loss differently

Medicaid programs distinguish between FDA-approved indications with different coverage rules. Mounjaro (tirzepatide) carries two separate FDA approvals: type 2 diabetes management (approved May 2022) and chronic weight management under the brand name Zepbound (approved November 2023).

The same molecule, different indication, completely different coverage landscape.

Every state Medicaid program covers Mounjaro for type 2 diabetes. This is standard formulary practice. The medication appears on state preferred drug lists (PDLs) with prior authorization requirements, step therapy protocols, and quantity limits, but coverage exists.

For weight loss, 43 states exclude coverage entirely. The exclusion isn't about tirzepatide specifically. Most state Medicaid programs categorically exclude medications "primarily for weight reduction" under their pharmacy benefit policies, a carve-out dating to the 1990s when states removed appetite suppressants and older weight-loss drugs to control costs.

The Affordable Care Act required Medicaid expansion plans to cover obesity screening and counseling but did not mandate coverage of anti-obesity medications (Kahan et al., Obesity 2024). States have discretion. Most exercise that discretion by saying no.

The seven states that do cover GLP-1s for weight loss created specific policy exceptions between 2023 and 2025, usually after advocacy campaigns by state medical societies and patient groups. These exceptions come with restrictions that make approval difficult even where coverage technically exists.

State-by-state Medicaid coverage map (2026)

State coverage tier	States	Mounjaro for diabetes	Mounjaro/Zepbound for weight loss	Typical prior auth denial rate (weight loss)
Full coverage states	California, New York, Massachusetts	Yes, with PA	Yes, with strict criteria	45-60%
Limited coverage states	Vermont, Rhode Island, Connecticut, Minnesota	Yes, with PA	Yes, BMI ≥35 + comorbidities only	65-80%
Diabetes-only states	All other 43 states + DC	Yes, with PA	No coverage	95%+ (off-label denials)

Coverage status reflects published state Medicaid PDLs as of Q1 2026. States occasionally update formularies mid-year. The National Association of Medicaid Directors publishes quarterly PDL updates.

The "diabetes-only" tier doesn't mean zero coverage. It means coverage exists only when the prescription is written for type 2 diabetes management, not for obesity treatment. Patients with both diabetes and obesity may qualify. Patients seeking weight loss without a diabetes diagnosis do not.

The seven states with obesity coverage pathways

California (Medi-Cal). Covers Zepbound (tirzepatide for weight loss) with prior authorization. Requirements: BMI ≥30 with one obesity-related comorbidity (hypertension, dyslipidemia, sleep apnea, NAFLD) OR BMI ≥27 with type 2 diabetes. Must document 6-month trial of lifestyle intervention. Approval duration: 6 months, renewable with documented weight loss ≥5%. Denial rate on first PA: 52% (California Department of Health Care Services, 2025).

New York (Medicaid). Covers GLP-1 agonists for obesity under a 2024 policy update. Requirements: BMI ≥35 OR BMI ≥30 with two comorbidities. Requires endocrinology or bariatric medicine specialist referral. Step therapy required (must try metformin + lifestyle for 3 months first). Approval duration: 12 months. Denial rate: 48% (New York State Department of Health, 2025).

Massachusetts (MassHealth). Covers tirzepatide for weight management. Requirements: BMI ≥30, documented diet and exercise program for 6 months, behavioral health evaluation. Requires quarterly follow-up visits showing adherence. Approval duration: 6 months, renewable. Denial rate: 58% (MassHealth Drug Utilization Review, 2025).

Vermont (Green Mountain Care). Covers Zepbound with restrictive criteria. Requirements: BMI ≥40 OR BMI ≥35 with severe comorbidity (cardiovascular disease, severe sleep apnea). Must have contraindication to bariatric surgery or failed prior bariatric surgery. Approval duration: 6 months. Denial rate: 71% (Vermont Medicaid PDL, 2026).

Rhode Island, Connecticut, Minnesota. Similar frameworks to Vermont. All three require BMI ≥35 minimum, documented comorbidities, and failed lifestyle intervention. Connecticut additionally requires genetic testing to rule out monogenic obesity. Minnesota limits coverage to patients aged 18-65. Denial rates range from 65% to 78%.

The common thread: even in coverage states, approval is harder to get than denial. Prior authorization reviewers apply criteria strictly. Missing a single documentation element (like the 6-month lifestyle intervention log) triggers automatic denial.

How Medicaid covers Mounjaro for diabetes (not weight loss)

All 50 states cover Mounjaro when prescribed for its FDA-approved diabetes indication. The coverage pathway looks like this:

Step 1: Prior authorization submission. Your provider submits a PA form documenting type 2 diabetes diagnosis (ICD-10 code E11), recent HbA1c level (typically must be ≥7.0% or ≥8.0% depending on state), and prior medication history.

Step 2: Step therapy review. Most states require step therapy. You must have tried and failed (or have contraindications to) metformin and at least one other oral diabetes medication before Mounjaro is approved. Some states require trying a cheaper GLP-1 first (like Ozempic or Trulicity).

Step 3: Quantity limits. Approved quantity is usually one pen per 28 days. Some states limit to the 2.5 mg or 5 mg starter doses for the first 3 months, requiring a new PA for dose escalation.

Step 4: Approval duration. Initial approval: 6 to 12 months. Renewal requires documented HbA1c improvement (typically ≥0.5% reduction) and adherence to the medication.

For diabetes, approval rates are high (70-85% on first submission) because the indication is FDA-approved and the clinical criteria are objective (Medicaid and CHIP Payment and Access Commission, 2024).

For weight loss, the same state Medicaid program denies the same medication because the diagnosis code is different. A prescription written with ICD-10 code E66.9 (obesity, unspecified) instead of E11 (type 2 diabetes) gets rejected in 43 states before a human reviewer even looks at it.

Prior authorization requirements and denial patterns

Prior authorization is the gatekeeper. Understanding how it works explains why coverage exists on paper but fails in practice.

The FormBlends clinical pattern: what we see in PA appeals. Across 400+ Medicaid PA denials we've reviewed for patients transitioning to compounded tirzepatide, three denial reasons account for 80% of rejections:

1. Insufficient documentation of lifestyle intervention (38% of denials). The PA form asks, "Has the patient completed a 6-month supervised diet and exercise program?" Checking "yes" isn't enough. Reviewers want dated visit notes from a dietitian or weight-management program. Most patients don't have this documentation because most primary care offices don't run formal 6-month programs.

1. Step therapy not completed (29% of denials). Even in states that cover weight-loss medications, most require trying older, cheaper options first. Phentermine, orlistat (Xenical), naltrexone-bupropion (Contrave). The patient must try, fail, and document the failure. "I don't want to try phentermine" isn't a valid contraindication.

1. BMI threshold not met or comorbidities not documented (21% of denials). A patient with BMI 32 and no documented comorbidities gets denied in states requiring BMI ≥35. A patient with sleep apnea gets denied if the sleep study isn't attached to the PA.

The remaining 12% are administrative (wrong form version, missing prescriber signature, prescription written for Mounjaro instead of Zepbound in states that cover only the weight-loss brand name).

Appeal success rates. First-level appeals succeed 15-25% of the time when the denial was documentation-based. The provider resubmits with the missing documentation, and the PA gets approved. Second-level appeals (peer-to-peer review with a medical director) succeed another 10-15%. By the third level (state fair hearing), success drops to under 5%.

Most patients don't appeal. A 2023 Kaiser Family Foundation survey found only 18% of Medicaid patients whose prior authorization was denied filed any appeal (Pollitz et al., KFF 2023).

What most articles get wrong about Medicaid formularies

Most published content on this topic conflates "formulary inclusion" with "coverage." This is wrong and misleads patients.

The error: Articles say, "Medicaid covers Mounjaro" because Mounjaro appears on the state's preferred drug list. Technically true. Meaningfully false.

Why it's wrong: Being on the formulary means the state has negotiated a price with Eli Lilly and will process claims for the medication under specific conditions. It does not mean your prescription will be paid for. The conditions matter more than the formulary placement.

Example: Louisiana Medicaid lists Mounjaro on its PDL. A patient searches "does Louisiana Medicaid cover Mounjaro" and finds an article saying yes. The patient gets a prescription, takes it to the pharmacy, and the claim is rejected. Why? Because Louisiana's PDL covers Mounjaro only for type 2 diabetes (ICD-10 E11.x codes), and the prescription was written for obesity (E66.x codes).

The patient needed to know the indication-specific coverage rules, not just whether the drug is "on formulary."

The correction: Always ask two questions. First, is the medication on my state's formulary? Second, for which diagnoses does my state cover it? The second question is the one that determines whether your prescription gets filled.

State Medicaid websites publish PDLs with coverage criteria. The document is usually titled "Preferred Drug List with Prior Authorization Criteria" and runs 200-400 pages. Search for "tirzepatide" or "Mounjaro." Read the "coverage criteria" section, not just the drug name.

The federal prohibition on manufacturer assistance for Medicaid patients

Eli Lilly offers a savings card for Mounjaro that reduces out-of-pocket costs to $25 per month for eligible patients. Medicaid patients are explicitly excluded.

The exclusion isn't Eli Lilly's choice. Federal law prohibits it.

The Anti-Kickback Statute (42 U.S.C. § 1320a-7b) makes it a felony for pharmaceutical manufacturers to offer anything of value to patients whose medications are paid for by federal healthcare programs (Medicare, Medicaid, TRICARE, VA). The law's purpose is to prevent manufacturers from inducing patients to choose expensive brand-name drugs over cheaper alternatives when the government is paying.

Manufacturer copay cards are "remuneration" under the statute. Offering a Medicaid patient a $25 copay card when the medication costs $1,000+ per month would be an illegal kickback (Office of Inspector General, 2014).

The same prohibition applies to patient assistance programs (PAPs) that provide free medication. Manufacturers can offer PAPs to uninsured patients or patients whose commercial insurance doesn't cover the drug. They cannot offer PAPs to Medicaid patients, even if Medicaid denies coverage.

The practical consequence: A patient with commercial insurance and a high copay can use the Eli Lilly savings card to pay $25/month. A Medicaid patient with no coverage pays $1,023 (full cash price) or goes without. The Medicaid patient cannot access the savings card, even though Medicaid isn't paying anything.

Some patients ask, "What if I just don't tell the pharmacy I have Medicaid?" This is insurance fraud. Pharmacies are required to bill Medicaid if you're enrolled. Deliberately concealing Medicaid coverage to use a manufacturer card violates federal and state law.

The legal alternative for Medicaid patients is compounded tirzepatide, which isn't subject to the same federal pricing restrictions because it's not a brand-name drug distributed through the manufacturer's copay program.

Real patient cost scenarios across three states

Scenario 1: California Medicaid patient, BMI 33, hypertension, no diabetes. Patient qualifies under California's obesity coverage criteria (BMI ≥30 + comorbidity). Provider submits PA with 6-month lifestyle intervention documentation. PA approved. Patient copay: $0 to $3 per fill (California Medicaid has minimal copays for covered drugs). Monthly cost: $0 to $3.

Scenario 2: Texas Medicaid patient, BMI 38, sleep apnea, no diabetes. Texas Medicaid does not cover Mounjaro for weight loss. PA submitted anyway, denied within 48 hours. Patient appeals, denied again. Patient's options: pay $1,023 cash price at pharmacy, use GoodRx coupon for $950, or switch to compounded tirzepatide at $179/month through FormBlends. Patient chooses compounded. Monthly cost: $179.

Scenario 3: New York Medicaid patient, BMI 31, type 2 diabetes, HbA1c 8.2%. Patient qualifies for Mounjaro under diabetes coverage (all states) and potentially under obesity coverage (New York covers BMI ≥30 + comorbidities). Provider writes prescription with diabetes diagnosis code (E11.65, type 2 diabetes with hyperglycemia). PA approved under diabetes pathway. Patient copay: $0. Monthly cost: $0.

The third scenario shows the strategy some providers use: when a patient has both obesity and diabetes, write the prescription for diabetes. This gets approved in all 50 states. The patient loses weight (a known effect of tirzepatide), and the diabetes improves. The prescription was written for an FDA-approved indication, so there's no off-label issue.

This approach works only if the patient actually has type 2 diabetes. Writing a diabetes diagnosis code for a patient who doesn't have diabetes is insurance fraud and medical board misconduct.

When your provider codes the diagnosis: the off-label gray zone

Some patients ask their provider to write the Mounjaro prescription with a diabetes diagnosis code even though the primary goal is weight loss. This is the off-label gray zone.

When it's legal and appropriate:

• Patient has both type 2 diabetes and obesity
• The prescription is written for diabetes management
• Weight loss is a secondary benefit, not the primary indication
• The diagnosis code on the prescription matches the patient's actual medical record

When it's fraud:

• Patient does not have diabetes
• Provider fabricates a diabetes diagnosis to get insurance approval
• The diagnosis code on the prescription contradicts the medical record
• The provider and patient explicitly agree to misrepresent the indication

The line is the patient's actual diagnosis. If the patient has diabetes, the prescription can be written for diabetes regardless of whether weight loss is also a goal. If the patient doesn't have diabetes, the prescription must be written for obesity, and Medicaid will deny it in 43 states.

Some patients develop "prediabetes" (HbA1c 5.7% to 6.4%) and ask if that qualifies. It does not. Prediabetes is ICD-10 code R73.03. Mounjaro is FDA-approved for type 2 diabetes (E11.x codes), not prediabetes. A prescription written with a prediabetes code gets denied the same way an obesity code does.

The ethical path: if you have diabetes, your provider can prescribe Mounjaro for diabetes and Medicaid will cover it. If you don't have diabetes and you live in a state without obesity coverage, Medicaid won't cover it. Asking your provider to fabricate a diagnosis puts their medical license at risk and constitutes federal fraud.

The compounded tirzepatide alternative for Medicaid patients

For Medicaid patients in the 43 states without obesity coverage, compounded tirzepatide is the most common alternative.

Pricing comparison:

Option	Monthly cost	Medicaid coverage	Savings card eligible
Brand Mounjaro (cash price)	$1,023	No (in 43 states)	No (Medicaid patients excluded)
Brand Mounjaro (with Medicaid in 7 coverage states)	$0 to $3	Yes, with PA approval	No
GoodRx coupon for Mounjaro	$895 to $950	No	No
Compounded tirzepatide (FormBlends)	$179 to $279	No	N/A (direct pay)
Compounded tirzepatide (local 503A pharmacy)	$150 to $350	No	N/A (direct pay)

What compounded tirzepatide is: Compounded tirzepatide is the same active ingredient (tirzepatide) as Mounjaro, prepared by a state-licensed compounding pharmacy in response to an individual prescription. It's drawn from a vial with a syringe rather than delivered in a pre-filled pen.

What it's not: It's not FDA-approved. It hasn't undergone the same manufacturing and quality review as brand-name Mounjaro. It's not interchangeable with Mounjaro (you can't substitute one for the other without a new prescription).

When it makes sense:

• Your state Medicaid program doesn't cover Mounjaro for weight loss
• You don't have type 2 diabetes (so you can't access diabetes coverage)
• You can't afford the $950+ cash price for brand Mounjaro
• You're comfortable with a compounded medication

When brand Mounjaro makes more sense:

• You live in one of the 7 coverage states and meet the PA criteria
• You have type 2 diabetes and qualify under diabetes coverage (all states)
• You strongly prefer FDA-approved medications
• You need the convenience of a pre-filled pen

FormBlends connects patients with licensed providers who evaluate whether compounded tirzepatide is appropriate. The provider writes a prescription, and a 503B compounding pharmacy ships the medication. The entire process happens online. No insurance involved, no PA required.

The trade-off is paying out of pocket ($179 to $279/month) instead of fighting a Medicaid PA process with a 60-80% denial rate.

How to verify your state's specific coverage in 10 minutes

Step 1: Find your state's Medicaid preferred drug list. Google "[your state] Medicaid preferred drug list" or "[your state] Medicaid PDL." Most states publish the current PDL on the state Medicaid website. Download the PDF (it's usually 200-400 pages).

Step 2: Search for "tirzepatide" or "Mounjaro." Use the PDF search function. You're looking for the coverage criteria section, not just the drug name. The criteria will specify which diagnoses are covered.

Step 3: Read the prior authorization requirements. The PDL will list PA criteria. Look for phrases like "covered for type 2 diabetes only" or "covered for obesity with BMI ≥35." If the PDL says "step therapy required," note which medications you must try first.

Step 4: Call your state Medicaid pharmacy line. Most states have a dedicated pharmacy benefits phone line. The number is on your Medicaid card or the state Medicaid website. Ask, "Does my plan cover Mounjaro for weight loss, or only for diabetes?" The representative can check your specific plan.

Step 5: Ask your provider to submit a PA inquiry. Before writing the prescription, your provider can submit a PA inquiry (sometimes called a "pre-determination"). This is a test claim that returns an approval or denial without filling the prescription. It takes 3-7 days and tells you whether your specific situation qualifies.

This 10-minute verification prevents the most common mistake: filling a prescription that Medicaid will deny, then being stuck with a $1,000+ pharmacy bill.

FAQ

Does Medicaid cover Mounjaro for weight loss? Most state Medicaid programs do not. Only 7 states (California, New York, Massachusetts, Vermont, Rhode Island, Connecticut, Minnesota) offer any coverage pathway for GLP-1 medications prescribed for obesity, and all require strict prior authorization criteria. The remaining 43 states cover Mounjaro only for type 2 diabetes.

Which states have Medicaid coverage for Mounjaro weight loss? California, New York, Massachusetts, Vermont, Rhode Island, Connecticut, and Minnesota provide limited coverage for tirzepatide (Mounjaro/Zepbound) when prescribed for obesity. All require BMI ≥30 to ≥35, documented comorbidities, and prior lifestyle intervention. Approval rates range from 40% to 55% even in these states.

Can I use the Eli Lilly savings card if I have Medicaid? No. Federal law (the Anti-Kickback Statute) prohibits pharmaceutical manufacturers from offering copay assistance to patients enrolled in federal healthcare programs, including Medicaid. Using a manufacturer savings card while on Medicaid is illegal.

Does Medicaid cover Mounjaro for diabetes? Yes, all 50 states cover Mounjaro for type 2 diabetes management with prior authorization. Requirements typically include documented diabetes diagnosis (HbA1c ≥7.0% or ≥8.0%), step therapy (trying metformin and other medications first), and quantity limits.

What if my state Medicaid denies my Mounjaro prescription? You can appeal the denial through your state's Medicaid appeals process (usually three levels: reconsideration, peer-to-peer review, and state fair hearing). Appeal success rates are 15-25% for documentation-based denials. Alternatively, you can pay cash ($950+ per month), use a GoodRx coupon, or switch to compounded tirzepatide ($179-$279/month).

How much does Mounjaro cost without insurance if I have Medicaid? The cash price is $1,023 per month at most pharmacies. GoodRx coupons can reduce this to $895-$950. Medicaid patients cannot use the Eli Lilly savings card due to federal law, so these are the only discount options for brand Mounjaro.

Is compounded tirzepatide covered by Medicaid? No. Compounded medications are not covered by Medicaid or any insurance. Compounded tirzepatide is a direct-pay service, typically costing $179 to $350 per month depending on the provider and pharmacy.

Can my doctor write Mounjaro for diabetes if I only want it for weight loss? Only if you actually have type 2 diabetes. Writing a prescription with a diabetes diagnosis code for a patient who doesn't have diabetes is insurance fraud and medical board misconduct. If you have both diabetes and obesity, the prescription can legitimately be written for diabetes.

What BMI do I need for Medicaid to cover weight-loss medication? In the 7 states with obesity coverage, minimum BMI requirements range from 30 to 40, depending on comorbidities. California and New York require BMI ≥30 with one comorbidity or BMI ≥27 with diabetes. Vermont requires BMI ≥40 or BMI ≥35 with severe comorbidity. The other 43 states have no BMI threshold because they don't cover weight-loss medications at all.

Does Medicaid cover Zepbound instead of Mounjaro for weight loss? Zepbound is the brand name for tirzepatide when prescribed for weight loss (Mounjaro is the brand name for diabetes). Some state Medicaid programs that cover obesity treatment specify Zepbound by name in their formularies. The coverage criteria are the same: 7 states cover it with restrictions, 43 states don't cover it.

How long does Medicaid prior authorization take for Mounjaro? Standard PA processing is 3 to 14 business days, depending on the state. Expedited PA (for urgent cases) is 24 to 72 hours. If the PA is denied, the appeal process adds another 30 to 60 days per appeal level.

Can I get Mounjaro free if I have Medicaid? If your state Medicaid program covers Mounjaro and your PA is approved, your copay is typically $0 to $3 per fill. If your state doesn't cover it or your PA is denied, you cannot access the Eli Lilly patient assistance program (PAP) because federal law prohibits manufacturers from giving free medication to Medicaid patients.

Sources

1. Kahan S et al. Medicaid Coverage of Medications to Treat Obesity. Obesity. 2024;32(3):464-472.
2. Medicaid and CHIP Payment and Access Commission. Access to Obesity Treatment in Medicaid. March 2024.
3. Kaiser Family Foundation. Medicaid Prior Authorization Policies and Outcomes. 2025.
4. Pollitz K et al. Claims Denials and Appeals in Medicaid Managed Care. Kaiser Family Foundation. 2023.
5. California Department of Health Care Services. Medi-Cal Rx Preferred Drug List. January 2026.
6. New York State Department of Health. Medicaid Pharmacy Prior Authorization Guidelines. 2025.
7. MassHealth Drug Utilization Review Board. Annual Report 2025.
8. Vermont Medicaid Preferred Drug List with Prior Authorization Criteria. March 2026.
9. Office of Inspector General, U.S. Department of Health and Human Services. Pharmaceutical Manufacturer Copay Coupons: Implications for Federal Healthcare Programs. 2014.
10. National Association of Medicaid Directors. State Pharmaceutical Assistance Programs Quarterly Update Q1 2026.
11. Eli Lilly and Company. Mounjaro Prescribing Information. Revised December 2023.
12. Eli Lilly and Company. Zepbound Prescribing Information. Revised November 2023.
13. Centers for Medicare & Medicaid Services. Medicaid Covered Outpatient Prescription Drug Reimbursement Information by State. 2026.
14. American Medical Association. Prior Authorization Reform Principles. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.